Back to Journals » Medicolegal and Bioethics » Volume 2

OxyContin, prescription opioid abuse and economic medicalization

Authors Poitras G

Received 17 September 2012

Accepted for publication 23 October 2012

Published 23 November 2012 Volume 2012:2 Pages 31—43


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Geoffrey Poitras

Faculty of Business Administration, Simon Fraser University, Vancouver, BC, Canada

Abstract: This paper examines the relevance of OxyContin diversion and abuse to the economic medicalization of substance abuse and addiction. Given that medicalization is the general social process of nonmedical problems being transformed into medical problems, economic medicalization occurs where the motivation for the transformation is commercial profitability or, in a corporate context, achieving the objective of shareholder wealth maximization. After considering potential conflicts between medical ethics and business ethics, practical aspects of economic medicalization are detailed by considering the methods used to market OxyContin by Purdue Pharma. Illegal practices are identified and contrasted with legal practices that facilitated economic medicalization. Implications of medicalization research for designing public heath solutions to the epidemic of prescription opioid abuse are discussed.

Keywords: medicalization, OxyContin, prescription drug abuse, medical ethics

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]